The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab-Reference-Cited by-同舟云学术

The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab

Published:2019-04-29 Issue:4 Volume:25 Page:676-684
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Carcao Manuel¹^ORCID,Escuriola‐Ettingshausen Carmen²,Santagostino Elena³,Oldenburg Johannes⁴^ORCID,Liesner Ri⁵,Nolan Beatrice⁶,Bátorová Angelika⁷,Haya Saturnino⁸,Young Guy⁹^ORCID,

Affiliation:

1. Division of Haematology/Oncology, Department of Paediatrics and Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children University of Toronto Toronto Ontario Canada

2. Haemophilia Centre Rhine Main Möerfelden‐Walldorf Germany

3. Maggiore Hospital Policlinico Angelo Bianchi Bonomi Hemophilia and Thrombosis Center Milan Italy

4. Institute of Experimental Haematology and Transfusion Medicine University of Bonn Bonn Germany

5. Haemophilia Centre, Great Ormond Street Hospital for Children NHS Trust Haemophilia Centre London UK

6. Our Lady's Children's Hospital Crumlin Dublin Ireland

7. Department of Haematology and Transfusion Medicine and National Haemophilia Centre University Hospital, Comenius University Bratislava Slovakia

8. Unit for Congenital Bleeding Disorders Hospital Universitario y Politécnico La Fe Valencia Spain

9. Children's Hospital Los Angeles University of Southern California Keck School of Medicine Los Angeles California

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.13762

Reference37 articles.

1. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study

2. Immune tolerance induction in hemophilia;Mancuso EM;Haemophilia,2015

3. Key issues in inhibitor management in patients with haemophilia;Gomez K;Blood Transfus,2014

4. Meta-analysis on incidence of inhibitors in patients with haemophilia A treated with recombinant factor VIII products

5. A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The evolving landscape of gene therapy for congenital severe hemophilia: a 2024 state of the art;Bleeding, Thrombosis and Vascular Biology;2024-09-04

2. Low‐dose immune tolerance induction for severe hemophilia A inhibitor patients: Immunosuppressants are generally not necessary for inhibitor‐titer below 200 BU/mL;Pediatric Investigation;2024-06

3. Clinical and economic burden of immune tolerance induction in entire patients with hemophilia A: Insights from a real-world Korean setting;Thrombosis Research;2024-05

4. Bleeding control improves after switching to emicizumab: Real‐world experience of 177 children in the PedNet registry;Haemophilia;2024-04-05

5. Race and ethnicity and the success of immune tolerance induction among people with severe haemophilia A in the United States;Haemophilia;2024-03-10